MIRAPEX has a well-established safety and tolerability profile
Learn more
Learn more about
diagnostic criteria for
Parkinson's disease*
Click here
*  You will need Adobe® Reader®  to download
this file. If you don't have
Adobe Reader, click here
for a free and secure
download.

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

MIRAPEX helps you reserve the use of levodopa until patients need it most1,14

At 4 years, MIRAPEX patients needed 38% less levodopa than patients taking levodopa alone1

Mirapex helps improve ADL and UPDRA scores by saving levodopa and delaying major motor complications

The Parkinson Study Group. JAMA, 2000; Archives of Neurology, 2004.
Multicenter, parallel-group, double-blind, randomized, controlled trial in 301 patients with early PD (Hoehn and Yahr stages I-III). Objective: to compare initial treatment with MIRAPEX vs levodopa with respect to the development of dopaminergic motor complications. Dosing: (2 year): subjects were escalated initially to a daily dose of MIRAPEX 1.5 mg or levodopa 75/300 mg; (4 year): the maintenance dose of MIRAPEX was maintained throughout the trial; supplemental levodopa was permitted if needed. Patients were titrated to a maximum dose of MIRAPEX 4.5 mg or levodopa 600 mg. Primary outcome variables were time to the first occurrence of dopaminergic complications: wearing-off, dyskinesia, or "on"-"off " fluctuations. Secondary outcome variables included changes in UPDRS (Unified Parkinson's Disease Rating Scale) scores. Conclusion: initial treatment with MIRAPEX resulted in fewer incidences of dyskinesia and wearing-off compared with levodopa.

  • Patients taking MIRAPEX (average of 2.78 ± 1.1 mg/day) took an average of 268 mg less levodopa per day

Initiating therapy with a dopamine agonist can provide long-term treatment benefits

  • Dopamine agonists reduce the risk of motor complications vs levodopa14
  • Dopamine agonist monotherapy provides antiparkinsonian efficacy in early Parkinson's disease4,14-17
  • Patients with Parkinson's disease may be maintained on dopamine agonist monotherapy for several years15
  • As Parkinson's disease advances, supplemental levodopa provides clinical benefits14,15,18

The use of dopamine agonists to delay and reduce the quantity of levodopa administration has the potential advantages of :19

  • Reducing the incidence of levodopa-related motor complications
  • Avoiding the priming effect of levodopa
  • Reducing the cumulative exposure to levodopa
 
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.